Bristol Myers Squibb — Third Quarter 2026 Earnings Summary

Bristol Myers Squibb reported third-quarter 2026 total revenues of $13.1 billion, representing a 7% increase compared to the same period in 2025. The company's Growth Portfolio revenues rose 12% to $7.7 billion, driven by products including Opdivo Qvantig, Breyanzi, and Camzyos, while the Legacy Portfolio increased 1% to $5.4 billion. On a non-GAAP basis, earnings per share were $1.35, and the company raised its full-year 2026 revenue guidance to a range of $49.75 billion to $50.25 billion. Recent pipeline milestones include the FDA approval of Zenbexus for multiple myeloma and positive Phase 3 data for several other therapeutic candidates.